Navigation Links
Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
Date:2/27/2008

ties Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our Company's expectations and projections. The most significant of such risks and uncertainties include, but are not limited to, our ability, and the ability of King Pharmaceuticals Research and Development, Inc. and other pharmaceutical companies, if any, with whom we may license our Aversion(R) Technology, to obtain necessary regulatory approvals and commercialize products utilizing the Aversion(R) Technology, the ability to avoid infringement of patents, trademarks and other proprietary rights or trade secrets of third parties, and the ability to fulfill the FDA's requirements for approving our product candidates for commercial manufacturing and distribution in the United States, including, without limitation, the adequacy of the results of the clinical studies completed to date and the results of other clinical studies, to support FDA approval of our product candidates, the adequacy of the development program for our product candidates, changes in regulatory requirements, adverse safety findings relating to our product candidates, the risk that the FDA may not agree with our analysis of its clinical studies and may evaluate the results of these studies by different methods or conclude that the results of the studies are not statistically significant, clinically meaningful or that there were human errors in the conduct of the studies or otherwise, the risk that further studies of our product candidates are not positive, and the uncertainties inherent in scientific research, drug development, clinical trials, the regulatory approval process, and commercial supply. You are encouraged to review other important risk factors relating to our operations on our web site at http://www.acur
'/>"/>

SOURCE Acura Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion(R) (Abuse-Deterrent) Technology
2. Acura Pharmaceuticals, Inc. Announces Implementation of Reverse Stock Split and New Trading Symbol: ACPH
3. Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director
4. Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
9. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
10. ACG Announces Major Gift by Salix Pharmaceuticals, Inc.
11. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2014)... team of researchers was the first in the world ... a tumour of the jaw. , Ameloblastoma is an ... treatment. Ameloblastoma is most often found in the posterior ... often resulting in tissue deficiencies in the jaws as ... therapy could reduce the need for surgery and the ...
(Date:4/24/2014)... the influenza pH1N1 virus caused the first flu pandemic ... May 2009 and killed more than 50 people in ... mainly during flu epidemics (winter/spring seasons). , Infections ... complicated illnesses. World Health Organization has recommended Tamiflu for ... disadvantage of this drug is that it targets viral ...
(Date:4/23/2014)... April 24, 2014 Pregnant immigrants from Sub-Saharan ... increased monitoring during pregnancy, according to new research ... today in the British Journal of Obstetrics ... and eclampsia rates among immigrants and native-born women ... (Ontario), Denmark, Sweden, Spain (Catalonia and Valencia) and ...
(Date:4/23/2014)... University researcher is looking to give exercise enthusiasts the ... latest research shows that a cyber buddy can help. ... for Health Journal , is the first to indicate ... motivator during exercise, a software-generated partner also can be ... isn,t real can still motivate people to give greater ...
(Date:4/23/2014)... pathway that helps prevent new cells from receiving too ... been directly linked to cancer and other diseases. , ... the end of cell division, the enzyme Cdc14 activates ... are fully repaired before the parent cell distributes copies ... safeguard against some of the most devastating genome errors, ...
Breaking Medicine News(10 mins):Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:Cyber buddy is better than 'no buddy' 2Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2
... Imaging Center of Excellence kicked off a two-day ... chemistry, engineering, physics, molecular biology, neurosciences and imaging ... "Molecular Imaging Symposium: Envisioning the Future ... at the Natcher Auditorium of the National Institutes ...
... ... Charities Nationwide , ... New York (PRWEB) May 6, 2010 -- Fisher House Foundation today announced ... Navigator , the nation’s premier charity-rating agency. This is the sixth consecutive 4-star rating ...
... PHD Virtual announces ... ... Technologies , pioneer and innovator in backup and recovery for virtual machines announced today the ... for the growing number of virtualized XenServer environments and is certified Citrix Ready® . ...
... ST. LOUIS A residential summer weight-loss camp markedly ... edition of Pediatrics reports. A Saint ... body mass index (BMI), physical fitness and blood pressure. ... to redirect the social environment to be successful," said ...
... brain, research suggests , THURSDAY, May 6 (HealthDay News) -- ... wandering, a new study suggests. , Canadian researchers asked 15 ... computer. As they read the passage, a sensor tracked their ... had been paying attention to what they were reading or ...
... ... of "super chocolate", has been found effective in aiding weight loss. Users say it ... ... 6, 2010 -- A special formulation of "super chocolate" has been fast increasing popularity ...
Cached Medicine News:Health News:Envisioning the future of neuroscience 2Health News:Envisioning the future of neuroscience 3Health News:Fisher House Foundation Gets Sixth Consecutive “Four-Star” Rating from Charity Navigator 2Health News:Fisher House Foundation Gets Sixth Consecutive “Four-Star” Rating from Charity Navigator 3Health News:PHD Virtual Technologies Meets the Need for Fully Integrated Data Protection with PHD Virtual Backup for Citrix XenServer 2Health News:PHD Virtual Technologies Meets the Need for Fully Integrated Data Protection with PHD Virtual Backup for Citrix XenServer 3Health News:PHD Virtual Technologies Meets the Need for Fully Integrated Data Protection with PHD Virtual Backup for Citrix XenServer 4Health News:The biggest winners: Summer campers 2Health News:Super Fat-Melting Chocolate Recipe Revealed 2Health News:Super Fat-Melting Chocolate Recipe Revealed 3
(Date:1/14/2014)... NineSigma , Inc., the leading innovation partner to ... , May 14-16, 2014 at the Global Center for ... This is the premier industry event ... through open innovation. Participants will learn how world-changing innovation ...
(Date:1/14/2014)... 14, 2014 Equashield ( http://www.equashield.com ... drugs, today announced that it has achieved 60% ...   Equashield,s closed systems reduce the ... and other medical professionals who prepare and administer ...
(Date:1/14/2014)... , Jan. 14, 2014 Spark Therapeutics , a ... its most advanced clinical program, a Phase 3 study for inherited ... Spark,s CEO, Jeffrey D. Marrazzo , is presenting this and ... Conference in San Francisco . Marrazzo said Spark ...
Breaking Medicine Technology:Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Equashield's Sales Grow by 60% in 2013 2Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness 2Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness 3
... NEW YORK, May 12, 2011 Promising study results published ... a novel medical device has the potential to revolutionize how ... the HIV epidemic. Conducted by EngenderHealth, a global reproductive health ... device, known as the Shang Ring, is highly acceptable to ...
... 12, 2011 Men and women infected with HIV ... sexual partners through initiation of oral antiretroviral therapy (ART), ... conducted by the HIV Prevention Trials Network (HPTN), a ... through cutting-edge biomedical, behavioral, and structural interventions. ...
Cached Medicine Technology:Novel Device Shows Promise for Reducing HIV Among Men 2Novel Device Shows Promise for Reducing HIV Among Men 3Initiation of Antiretroviral Treatment Protects Uninfected Sexual Partners from HIV Infection (HPTN Study 052) 2Initiation of Antiretroviral Treatment Protects Uninfected Sexual Partners from HIV Infection (HPTN Study 052) 3Initiation of Antiretroviral Treatment Protects Uninfected Sexual Partners from HIV Infection (HPTN Study 052) 4Initiation of Antiretroviral Treatment Protects Uninfected Sexual Partners from HIV Infection (HPTN Study 052) 5
... Diagnostics iQ®200 Automated Urine Microscopy Analyzer ... Recognition (APR®) software to classify urine ... report results. The iQ200 eliminates most ... interpret particle images by automating specimen ...
... The ISOPLATER® is an automatic ... load, streak and stack up to ... hour. Automated streaking results in substantial ... productivity, improves isolation rates, standardizes streaking ...
... a brand-new high technology state-of-the-art system offering ... and ease-of-use for every user. The flexible ... basic investigations as well as research purposes. ... This allows you to obtain the functionality ...
... Delphis™ is ideal for any clinical ... to performing a UDS procedure. Customize ... the options of a Pocket PC, ... Delphis with Bluetooth™ wireless technology allows ...
Medicine Products: